Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H13N3O |
Molecular Weight | 203.2404 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@H]1CN2C(=O)NC3=C2C(C1)=CC=C3
InChI
InChIKey=RKZSNTNMEFVBDT-MRVPVSSYSA-N
InChI=1S/C11H13N3O/c1-12-8-5-7-3-2-4-9-10(7)14(6-8)11(15)13-9/h2-4,8,12H,5-6H2,1H3,(H,13,15)/t8-/m1/s1
Molecular Formula | C11H13N3O |
Molecular Weight | 203.2404 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sumanirole is a novel dopamine agonist with high affinity and efficacy at D2 dopamine receptors and has a substantial degree of selectivity for the D2 receptor over other dopamine receptor subtypes. It had been in clinical trials for the treatment of Parkinson’s disease and restless leg syndrome but these studies were terminated for the efficacy reason.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL339 |
12.0 nM [Ki] | ||
Target ID: CHEMBL3138 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9057850 |
1.9 µM [Ki] | ||
Target ID: CHEMBL273 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9057850 |
92.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
1 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 49 Sources: |
Disc. AE: dizziness, Headaches... AEs leading to discontinuation/dose reduction: dizziness (1 pt) Sources: Headaches (1 pt) |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
Disc. AE: Nausea and vomiting, Dizziness... AEs leading to discontinuation/dose reduction: Nausea and vomiting (1 pt) Sources: Dizziness (1 pt) insomnia (1 pt) dizziness (1 pt) diarrhea (1 pt) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headaches | 1 pt Disc. AE |
1 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 49 Sources: |
dizziness | 1 pt Disc. AE |
1 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 1 mg, 1 times / day Route: oral Route: multiple Dose: 1 mg, 1 times / day Sources: |
unhealthy n = 49 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 49 Sources: |
Dizziness | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
Nausea and vomiting | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
diarrhea | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
dizziness | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
insomnia | 1 pt Disc. AE |
2 mg 1 times / day multiple, oral (unknown) Studied dose Dose: 2 mg, 1 times / day Route: oral Route: multiple Dose: 2 mg, 1 times / day Sources: |
unhealthy n = 59 Health Status: unhealthy Condition: restless legs syndrome Sex: M+F Food Status: UNKNOWN Population Size: 59 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
U-95666E: a potential anti-parkinsonian drug with anxiolytic activity. | 1997 Jul |
|
Effects of selective activation of dopamine D2 and D3 receptors on prolactin secretion and the activity of tuberoinfundibular dopamine neurons. | 1997 Sep 17 |
|
Sumanirole Pharmacia. | 2003 Jan |
|
Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease. | 2005 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17318839
1 to 16 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15980060
Sumanirole activated D2 receptor-stimulated mitogenesis with an EC50 of 4.6 nM, but it had no activity at D3 and D4 receptors in measurements of receptor-activated mitogenesis at concentrations up to 1 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 15:51:01 GMT 2023
by
admin
on
Sat Dec 16 15:51:01 GMT 2023
|
Record UNII |
3E93IV1U45
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB25219
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
9818479
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL419792
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
3E93IV1U45
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
DTXSID00870144
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
Sumanirole
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
179386-43-7
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
C76651
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
8051
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
100000089232
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY | |||
|
DB06477
Created by
admin on Sat Dec 16 15:51:02 GMT 2023 , Edited by admin on Sat Dec 16 15:51:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |